From Natasha Loder, Health Policy Editor at the Economist
GSK is not actually making this vaccine. It is Sanofi's vacccine. GSK is sharing its technology to make vaccines better (called an adjuvant) to any firm that wants them. (And quite a lot do.)
Earlier this year, CEO Emma Walmsley said they wanted to help by sharing their adjuvant, and it wasn't a commercial venture. Because, pandemic.
It was popular and is now used by covid vaccine makers such as @sanofi. Vir. @Innovax. Clover. Medicago Inc. Remarkable, actually.
So GSK are making a billion doses of adjuvant. They started, at risk, in May.
In the event GSK's tie-ups make money, firm says, "it will be invested in support of coronavirus related research and long-term pandemic preparedness, either through GSK’s internal investments, or with external partners."
Why? Because, pandemic.
Even if Vallance had some control over the UK's vaccine buying (and even the Telegraph admits in almost last paragraph that ministers make the decision)... and even if Sanofi does make a profit.... and even some of this goes to GSK, ......shareholders are not going to benefit.
But why spoil a juicy story with a few boring facts?